Signs exclusive marketing agreement with Sanofi Winthrop Pharmaceuticals to market its controlled-release oral nitroglycerin tablet Nitrong in the U.S. RPR states July 8 that the agreement will allow the company to build its cardiovascular franchise in the U.S. RPR recently gained approval for an extended-release version of the calcium channel blocker diltiazem, Dilacor XR ("The Pink Sheet" June 8, In Brief). The RPR release indicates that the companies may plan to position Nitrong as an alternative to nitroglycerin patches, noting that Nitrong dosing allows for a nitrate-free interval to avoid development of tolerance, which has been associated with patches.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth